Skip to main content

. 1967 Jan 21;1(5533):150–153. doi: 10.1136/bmj.1.5533.150

Effect of Lyndiol, an oral contraceptive, on breast cancer.

PMCID: PMC1840538 PMID: 6015649

150

Images in this article

Fig. 1
on p.151

Fig. 2
on p.151

Fig. 3
on p.151

Fig. 4
on p.151

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

CROWLEY L. G., MACDONALD I. DELALUTIN AND ESTROGENS FOR THE TREATMENT OF ADVANCED MAMMARY CARCINOMA IN THE POSTMENOPAUSAL WOMAN. Cancer. 1965 Apr;18:436–446. doi: 10.1002/1097-0142(196504)18:4<436::aid-cncr2820180407>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
HUGGINS C., MOON R. C., MORII S. Extinction of experimental mammary cancer. I. Estradiol-17beta and progesterone. Proc Natl Acad Sci U S A. 1962 Mar 15;48:379–386. doi: 10.1073/pnas.48.3.379. [DOI] [PMC free article] [PubMed] [Google Scholar]
LANDAU R. L., EHRLICH E. N., HUGGINS C. Estradiol benzoate and progesterone in advanced human-breast cancer. A combination found effective in advanced cases. JAMA. 1962 Nov 10;182:632–636. [PubMed] [Google Scholar]
STOLL B. A., ANDREWS J. T., MOTTERAM R., UPFILL J. ORAL CONTRACEPTIVES AND LIVER DAMAGE. Br Med J. 1965 Mar 13;1(5436):723–723. doi: 10.1136/bmj.1.5436.723-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
STRUTHERS R. A. Post-menopausal oestrogen production. Br Med J. 1956 Jun 9;1(4979):1331–1335. doi: 10.1136/bmj.1.4979.1331. [DOI] [PMC free article] [PubMed] [Google Scholar]

ACTIONS

RESOURCES